| Market Cap | 215.05Cr 188.3Cr 173.83Cr 162.32Cr 305.57Cr 20TCr 312.53Cr 2.09TCr 807.55Cr 10TCr 807.59Cr 789.87Cr 35TCr | P/E 2026 * |
-7.02x | P/E 2027 * | -5.75x |
|---|---|---|---|---|---|
| Enterprise Value | 215.05Cr 188.3Cr 173.83Cr 162.32Cr 305.57Cr 20TCr 312.53Cr 2.09TCr 807.55Cr 10TCr 807.59Cr 789.87Cr 35TCr | EV / Sales 2026 * |
52.2x | EV / Sales 2027 * | 58.3x |
| Free-Float |
99.55% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 67 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 215.05Cr | |
| +0.13% | +1.50% | +63.86% | +123.95% | 5.56TCr | |
| +6.76% | +22.83% | +91.66% | +101.42% | 5.22TCr | |
| +3.33% | +4.51% | -11.47% | -11.91% | 2.31TCr | |
| +1.32% | +6.22% | +4.07% | +415.45% | 2.24TCr | |
| +6.78% | +14.47% | +40.28% | -6.67% | 1.73TCr | |
| +0.97% | +5.01% | +31.23% | -32.10% | 1.59TCr | |
| -0.89% | +5.71% | +23.15% | +186.29% | 1.38TCr | |
| +9.96% | +19.81% | +157.65% | +320.70% | 1.35TCr | |
| +4.21% | +4.76% | +33.21% | - | 1.24TCr | |
| Average | +3.04% | +6.84% | +48.18% | +137.14% | 2.51TCr | |
| Weighted average by Cap. | +3.29% | +7.62% | +54.00% | +128.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.12Cr 3.61Cr 3.33Cr 3.11Cr 5.86Cr 389.7Cr 5.99Cr 40Cr 15Cr 192.25Cr 15Cr 15Cr 667.48Cr | 3.69Cr 3.23Cr 2.98Cr 2.79Cr 5.24Cr 348.93Cr 5.36Cr 36Cr 14Cr 172.14Cr 14Cr 14Cr 597.64Cr |
| Net income | -25Cr -22Cr -20Cr -19Cr -36Cr -2.36TCr -36Cr -243.21Cr -94Cr -1.17TCr -94Cr -92Cr -4.05TCr | -36Cr -31Cr -29Cr -27Cr -51Cr -3.36TCr -52Cr -346.09Cr -133.61Cr -1.66TCr -133.61Cr -130.68Cr -5.76TCr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
